TY - JOUR
T1 - Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
AU - AFFIRM-AHF investigators
AU - Ponikowski, Piotr
AU - Ohlsson, Marcus
AU - Jankowska, Ewa A.
PY - 2020
Y1 - 2020
N2 - Background: Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure. Methods: AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Singapore. Eligible patients were aged 18 years or older, were hospitalised for acute heart failure with concomitant iron deficiency (defined as ferritin
AB - Background: Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure. Methods: AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Singapore. Eligible patients were aged 18 years or older, were hospitalised for acute heart failure with concomitant iron deficiency (defined as ferritin
U2 - 10.1016/S0140-6736(20)32339-4
DO - 10.1016/S0140-6736(20)32339-4
M3 - Article
SN - 0140-6736
VL - 396
SP - 1895
EP - 1904
JO - The Lancet
JF - The Lancet
IS - 10200
ER -